** Shares of Neuroscience-focused biotech firm Cerevel
Therapeutics Holdings Inc CERE.O up 2.3% at $33.58
** Co appoints Susan Altschuller as chief financial officer
(CFO), effective May 15
** Altschuller, most recently, served as the CFO of
ImmunoGen Inc IMGN.O that focuses on developing antibody drug
conjugates for cancer patients
** CERE earlier in the month appointed Ron Renaud as
president and chief executive officer
** Co for Q1 posted a net loss of $0.67/shr, which widened
from $0.46/shr a year earlier
** Including session gains, CERE stock up ~6% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))